Icon

ADDITIONAL RESPONSIVE MUTATIONS NOW APPROVED FOR KALYDECO IN PATIENTS WITH CF AGED 4 MONTHS AND OLDER1

CHECK TREATMENT ELIGIBILITY

Enter your patient's mutations below

KALYDECO is a cystic fibrosis transmembrane conductance regulator (CFTR) potentiator indicated for the treatment of cystic fibrosis (CF) in patients age 4 months and older who have one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data.

Eligible

Please check to see if the mutation was entered correctly.

Results

Learn how to enter 2 or more mutations